Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. While preparing to go head to head in a rare disease market, the companies have signed up ...

Ionis Pharmaceuticals (NASDAQ:IONS) has entered into a license agreement under which Sobi receives exclusive rights in countries outside the U.S., Canada and China to commercialize olezarsen as a ...

CARLSBAD, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a ...

Ionis reported $705 million in 2024 revenue, topping guidance and boosted by two new product launches. U.S. Phase 3 results for Tryngolza in sHTG expected in H2 2025, targeting 2.3 million ...

CARLSBAD, Calif., March 26, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® receives exclusive ...